A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576
Recruiting
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Gender:
ALL
Ages:
Between 0 years and 45 years
Trial Updated:
07/11/2024
Locations: L'hôpital Universitaire des enfants Reine Fabiola (Huderf), Brussels, Not set +130 locations
Conditions: Leukemia, Acute Lymphoblastic
Register for Updates
Glymphatic MRI in Clinically Isolated Syndrome
NCT06274671
Recruiting
The brain possesses a system to get rid of unwanted substances, named Glymphatic System (GS). When this system is faulty, these accumulate, there is local inflammation, and progressive death of the cells. This occurs in neurological diseases including Parkinson's, or Alzheimer's. Inflammation and progressive death of the cells are also present in another neurological disorder, named Multiple Sclerosis (MS). Doctors think that GS dysfunction plays a role in MS too. In this research therefore, th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Royal Devon University Healthcare NHS Foundation Trust, Exeter, Not set +1 locations
Conditions: Clinically Isolated Syndrome
Register for Updates
Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.
NCT06501846
Recruiting
TITLE Pipelle® under Ultrasound Guidance (PUG) to investigate post-menopausal bleeding: Randomised Controlled Trial BACKGROUND Women who are suspected of having endometrial cancer (cancer of the inner lining of the womb) due to vaginal bleeding after the menopause must have a tissue sample taken from this area to determine whether there is an abnormality. One method of doing this is by using a small biopsy device (such as a Pipelle®) in the outpatient setting. This is referred to as an outpati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare Trust, London, Not set
Conditions: Endometrial Cancer, Post-Menopausal Bleeding, Endometrial Hyperplasia
Register for Updates
North West London Pebble Pathway: Automated OSA Diagnosis
NCT06507228
Recruiting
Patients with obstructive sleep apnoea (OSA) wait up to two years for a diagnostic test. Early diagnosis enables optimal treatment, mitigating risks including heart failure, lung disease, and stroke. Current diagnostic approaches are expensive (£391), time-consuming (\>1-hour interpretation), uncomfortable (cables/tubes/wires), and inequitable (multiple hospital visits). Overcoming all these limitations, we have designed and will investigate a straigh-to-test automated diagnostic pathway for OSA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Charing Cross Hospital, London, Not set
Conditions: Obstructive Sleep Apnea, Sleep Apnea
Register for Updates
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Florida, Jacksonville, Florida +407 locations
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Register for Updates
Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis
NCT04707976
Recruiting
A randomized, superiority, controlled, interventional, prospective, multicentre, post-market study of TAI with Navina™ Smart versus Standard Bowel Care performed in a population of 92 subjects suffering from Multiple Sclerosis and confirmed Neurogenic Bowel Dysfunction. The study is expected to last for a total of 8 weeks per subject with two scheduled site visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Aarhus University Hospital, Aarhus, Not set +8 locations
Conditions: Neurogenic Bowel (Disorder), Fecal Constipation, Fecal Incontinence, Multiple Sclerosis
Register for Updates
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
NCT02621645
Recruiting
Multi-center open-label randomized controlled trial to assess if early intervention (12.0-14.0 weeks) (study group) improves the outcome of TRAP sequence as compared to late intervention (16.0-19.0 weeks) (control group). The investigators will randomly assign women diagnosed with TRAP sequence diagnosed between 12.0 and 13.6 weeks to an early or late intervention group (1:1), using a web-based application and a computer-generated list with random permuted blocks of sizes 2 or 4 (www.sealedenvel... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Children's Memorial Hermann Hospital, Houston, Texas +13 locations
Conditions: Twin Reversal Arterial Perfusion Syndrome
Register for Updates
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
NCT04065269
Recruiting
ATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in the ARID1A gene.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: The Ottawa Hospital Cancer Centre, Ottawa, Ontario +8 locations
Conditions: Gynaecological Cancers
Register for Updates
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
NCT06488118
Recruiting
Respiratory viral infections can be a cause of significant illness, particularly in vulnerable individuals as seen in the COVID-19 pandemic. An underactive or overactive immune response can lead to ineffective resolution of inflammation after an infection, especially in people with airway diseases such as asthma. A better understanding of immune responses to infection that does not rely on cell or animal models is crucial to help develop better treatments for lung inflammation. An established m... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/08/2024
Locations: NIHR Cambridge Clinical Research Facility, Cambridge, Cambridgeshire
Conditions: Innate Immunity, Mucosal Immunity, Asthma, Viral Infection
Register for Updates
Capsule Sponge Study in Eosinophilic Oesophagitis
NCT06501274
Recruiting
Open pragmatic, descriptive single site study in adult patients with non-stenotic eosinophilic oesophagitis. To assess the clinical value of Capsule sponge in the assessment of treatment response in patients with known non-stenosing eosinophilic oesophagitis, as an alternative to gastroscopy in a real world setting. To assess patient preference for Capsule sponge or gastroscopy. All patients with non-stenosing eosinophilic oesophagitis who are reviewed in clinic that have not had reassessment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: East and North Herts NHS Trust, Stevenage, Hertfordshire
Conditions: Eosinophilic Esophagitis
Register for Updates
Study to Evaluate the Safety and Tolerability of EP0042
NCT04581512
Recruiting
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: Royal Perth Hospital, Perth, Western Australia +5 locations
Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Register for Updates
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
NCT04584853
Recruiting
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called abemaciclib.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/06/2024
Locations: Royal Cornwall Hospital, Truro, Cornwall +61 locations
Conditions: Breast Cancer Female
Register for Updates